{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T15:58:38Z","timestamp":1769875118782,"version":"3.49.0"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold><jats:bold> Background:\u2002<\/jats:bold> Mycophenolate mofetil (MMF) has the potential of decreasing acute rejection episodes early following renal transplantation. Pharmocokinetic monitoring of mycophenolic acid (MPA) trough levels is performed by many centers. MMF has also proved successful in improving long\u2010term graft function in patients with chronic allograft nephropathy (CAN). However, no data for long\u2010term monitoring of MPA in children have yet been published.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> MMF therapy with a dose of 600\u2003mg\/m<jats:sup>2<\/jats:sup> twice daily was initiated in 42 children (median age 9.4\u2003yr, range 1.4\u201315.1) after a median period of 3.8\u2003yr (range 1.0\u201310.6) post\u2010transplantation \u2013 according to significant increases in serum creatinine. CAN was diagnosed by renal biopsy and the amount of fibrosis was quantified with PicroSiriusRed staining. MMF therapy was combined with ciclosporin A and prednisolone. MPA\u2010C0\u2010levels, measured by high\u2010pressure liquid chromatography, were tested every 3\u2003months. In 12 children a full MPA area under the curve concentration (AUC) was measured. The glomerular filtration rate (<jats:italic>GFR<\/jats:italic>) was calculated at the start of MMF therapy and 2\u2003yr later.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> After initiation of MMF, the calculated <jats:italic>GFR<\/jats:italic> did not decrease further in 22 children and mean <jats:italic>GFR<\/jats:italic> remained stable for 2\u2003yr in the whole study group. There was a significant correlation between MPA levels 75\u2003min after administration and the full AUC (<jats:italic>r<\/jats:italic>\u2003=\u20030.94, p\u200a&lt;\u200a0.001) but no correlation between trough levels and AUC (<jats:italic>r<\/jats:italic>\u2003=\u2003\u22120.07, p\u200a&gt;\u200a0.05). The mean MPA trough level was 2.8\u2003\u00b1\u20031.3\u2003ng\/mL. The intra\u2010individual coefficient of variation was 2.6\u2003\u00b1\u20031.4. There was no correlation between mean MPA trough levels and <jats:italic>GFR<\/jats:italic> development after 2\u2003yr (<jats:italic>r<\/jats:italic>\u2003=\u20030.03, p\u200a&gt;\u200a0.05). In children with an MPA level below 1.2\u2003mg\/L (n\u2003=\u20035), the mean <jats:italic>GFR<\/jats:italic> decline was no different to those with a higher level (p\u200a&gt;\u200a0.05).<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Drug monitoring of MPA trough levels had no impact on long\u2010term graft function in kidney recipients. MPA levels taken 75\u2003min after administration showed a high correlation with MPA\u2010AUC whereas C0\u2010levels did not correlate. The value of C75 drug measurements for monitoring renal allograft survival will have to be judged in future studies.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2004.00229.x","type":"journal-article","created":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T15:20:15Z","timestamp":1094052015000},"page":"576-579","source":"Crossref","is-referenced-by-count":11,"title":["Long\u2010term follow\u2010up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long\u2010term graft function"],"prefix":"10.1111","volume":"18","author":[{"given":"L","family":"Pape","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JHH","family":"Ehrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Offner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,9]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200103150-00010"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3046.2001.00007.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000088664.77589.F0"},{"key":"e_1_2_5_5_2","first-page":"91","article-title":"Mycophenolate mofetil in pediatric renal transplantation","volume":"55","author":"Weber LT","year":"2003","journal-title":"Minerva Urol Nefrol"},{"key":"e_1_2_5_6_2","first-page":"925","article-title":"Pharmacokinetics of mycophenolate mofetil (RS61443): a short review","volume":"28","author":"Bullingham RES","year":"1996","journal-title":"Transplant Proc"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(00)00184-3"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.V133759","article-title":"The pharmacokinetic\u2010pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy","volume":"13","author":"Weber LT","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200304000-00003"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000078899.62040.E5"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(16)36251-4"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200115010-00004"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199907270-00018"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200004000-00005"},{"key":"e_1_2_5_15_2","first-page":"2273","article-title":"Excessive ciclosporine trough level variation with classic ciclosporine can be reduced with the new oral microemulsion ormulation of ciclosporine","volume":"28","author":"Bokenkamp A","year":"1996","journal-title":"Transplant Proc"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1681\/ASN.V981511","article-title":"Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients","volume":"9","author":"Weber LT","year":"1998","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2004.00229.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2004.00229.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:42:56Z","timestamp":1697218976000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2004.00229.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1111\/j.1399-0012.2004.00229.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2004.00229.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}